Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review

Abstract Background Programmed cell death protein 1 (PD-1) checkpoint inhibitors such as pembrolizumab are novel therapeutics used to treat various advanced malignancies. Immune-related adverse events are common, among the most serious of these toxicities is hemophagocytic lymphohistiocytosis (HLH),...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Chongya Zhai, Xuanhong Jin, Liangkun You, Na Yan, Jie Dong, Sai Qiao, Yuhong Zhong, Yu Zheng, Hongming Pan
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-01-01
coleção:	BMC Geriatrics
Assuntos:	Hemophagocytic lymphohistiocytosis Pembrolizumab Immune-related adverse event
Acesso em linha:	https://doi.org/10.1186/s12877-023-04625-3
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!